MediWound’s (MDWD) “Buy” Rating Reaffirmed at HC Wainwright

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $25.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 49.52% from the stock’s current price.

MediWound Price Performance

MediWound stock opened at $16.72 on Friday. MediWound has a one year low of $11.04 and a one year high of $24.00. The business has a fifty day moving average price of $17.24 and a 200-day moving average price of $17.64. The firm has a market capitalization of $180.34 million, a P/E ratio of -5.77 and a beta of 0.80.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the business earned ($0.24) earnings per share. Sell-side analysts expect that MediWound will post -2.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediWound

Large investors have recently added to or reduced their stakes in the business. MetLife Investment Management LLC bought a new stake in MediWound during the third quarter valued at $89,000. Rhumbline Advisers bought a new stake in MediWound during the second quarter valued at $131,000. Barclays PLC boosted its stake in MediWound by 311.3% during the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 8,449 shares during the period. Point72 Asset Management L.P. bought a new stake in MediWound during the third quarter valued at $212,000. Finally, Bank of New York Mellon Corp purchased a new stake in MediWound during the second quarter valued at about $342,000. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.